Compare CDNL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDNL | SVRA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 1.1B |
| IPO Year | N/A | 2009 |
| Metric | CDNL | SVRA |
|---|---|---|
| Price | $40.85 | $5.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $38.00 | $7.33 |
| AVG Volume (30 Days) | 291.7K | ★ 1.5M |
| Earning Date | 03-19-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.31 | N/A |
| Revenue Next Year | $10.23 | $430.87 |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.98 | $1.89 |
| 52 Week High | $39.80 | $7.01 |
| Indicator | CDNL | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 75.97 | 55.84 |
| Support Level | $23.33 | $5.47 |
| Resistance Level | N/A | $6.10 |
| Average True Range (ATR) | 2.35 | 0.29 |
| MACD | 0.64 | 0.05 |
| Stochastic Oscillator | 94.46 | 85.96 |
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. Its operations leverage a large highly skilled workforce and a fleet of specialized equipment to deliver wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).